Objective: To investigate the efficacy and safety of local intra-arterial chemotherapy combined with immune checkpoint inhibitors in the treatment of unresectable head and neck squamous cell carcinoma (HNSCC).
Methods: A retrospective analysis was conducted on the clinical data of eight patients diagnosed with unresectable HNSCC at our hospital from January to December 2023. All patients were diagnosed by pathological diagnosis and treated with intra-arterial chemotherapy combined with immune checkpoint inhibitors. The overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse reactions were observed.
Results: The study cohort consisted of seven men and one woman, with a median age of 58.4 ± 13.1 years. Five patients were at stage IVA, one at stage IVB, and two at stage IVC. One patient was lost to follow-up, and among the 7 patients with complete data, the ORR was 85.7%. The median PFS and OS in the overall population were not achieved, and the patient tolerated the treatment well with no significant adverse effects.
Conclusion: Local intra-arterial chemotherapy combined with immune checkpoint inhibitors is an important future exploration direction for the treatment of unresectable HNSCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.28121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Value of Changes in Combined Child-Pugh Class and ALBI Grade in Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Plus Targeted Therapy and PD-(L)1 Inhibitors.
J Hepatocell Carcinoma
March 2025
Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Purpose: This study aims to investigate liver function changes in hepatocellular carcinoma (HCC) patients treated with transcatheter intra-arterial therapy plus molecular targeted agents and programmed cell death-1 (ligand-1) inhibitors, and evaluate the prognostic significance of the combination of Child-Pugh (CP) class and albumin-bilirubin (ALBI) grade (CP/ALBI).
Methods: This is a retrospective study. A total of 149 patients from 2019 to 2023 in China were included.
Safety and Efficacy of Intra-Arterial Chemotherapy Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma.
Head Neck
March 2025
Department of Radiology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Objective: To investigate the efficacy and safety of local intra-arterial chemotherapy combined with immune checkpoint inhibitors in the treatment of unresectable head and neck squamous cell carcinoma (HNSCC).
Methods: A retrospective analysis was conducted on the clinical data of eight patients diagnosed with unresectable HNSCC at our hospital from January to December 2023. All patients were diagnosed by pathological diagnosis and treated with intra-arterial chemotherapy combined with immune checkpoint inhibitors.
Superselective intra-arterial cerebral infusion of chemotherapeutics after osmotic blood-brain barrier disruption in newly diagnosed or recurrent glioblastoma: technical insights and clinical outcomes from a single-center experience.
J Neurointerv Surg
March 2025
Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, New York, USA.
Background: Newly diagnosed glioblastoma (ndGBM) remains one of the most challenging malignancies to treat. Since the majority of patients experience tumor recurrence (rGBM) after first-line therapy, advancements in both initial and salvage treatments are essential.
Objective: We report our single-center experience on the feasibility and safety of superselective intra-arterial cerebral infusion (SIACI) with bevacizumab or cetuximab after osmotic blood-brain barrier disruption (oBBBd).
Comparison of selective intra-arterial to standard intravenous administration in percutaneous electrochemotherapy (pECT) for liver tumors.
Radiol Oncol
March 2025
6Clinic for Diagnostic and Interventional Radiology and Neuroradiology, WEGE Klinik, Bonn, Germany.
Background: Electrochemotherapy (ECT) is a local nonsurgical effective tumor treatment in the hand of the clinician for the treatment of patients with liver tumors or metastases. The study aimed to test the technical feasibility and safety of intra-arterial (i.a.
View Article and Find Full Text PDFCatheterization complications of intra-arterial chemotherapy for retinoblastoma.
J Neurointerv Surg
February 2025
Division of Interventional Neuroradiology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.
Background: Intra-arterial chemotherapy (IAC) is a growing method of therapy for retinoblastoma (Rb). There is an absence of data to support the safety of catheterization with intra-arterial infusion in this pediatric population OBJECTIVE: To focus on the non-ocular catheter/procedural-related complications that our practice has experienced in order to lay a foundation for practices interested in performing these procedures and hopefully, to help prevent them from occurring.
Methods: This is a retrospective review of the patient population with Rb treated in our center from May 2006 through May 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!